Smith & Nephew plc (LON:SN - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 1,121.01 ($15.12) and traded as high as GBX 1,391.21 ($18.77). Smith & Nephew shares last traded at GBX 1,387 ($18.71), with a volume of 1,199,494 shares traded.
Analysts Set New Price Targets
Several equities research analysts recently commented on SN shares. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the stock a "hold" rating in a research report on Wednesday, August 6th. JPMorgan Chase & Co. lifted their target price on shares of Smith & Nephew from GBX 1,357 to GBX 1,438 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank increased their price target on shares of Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the company a "hold" rating in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Smith & Nephew currently has a consensus rating of "Hold" and an average price target of GBX 1,379.33.
Read Our Latest Analysis on SN
Smith & Nephew Trading Up 0.4%
The firm has a market cap of £15.52 billion, a price-to-earnings ratio of 50.98, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The business has a 50 day moving average of GBX 1,240.27 and a 200 day moving average of GBX 1,129.30. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22.
Insider Buying and Selling at Smith & Nephew
In other news, insider Simon Lowth bought 355 shares of the stock in a transaction on Friday, August 22nd. The stock was purchased at an average cost of GBX 1,384 per share, with a total value of £4,913.20. Also, insider Jo Hallas purchased 389 shares of the business's stock in a transaction on Friday, August 22nd. The stock was acquired at an average price of GBX 1,384 per share, with a total value of £5,383.76. Over the last quarter, insiders bought 4,811 shares of company stock valued at $12,947,701. Corporate insiders own 0.19% of the company's stock.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Featured Stories
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
